SCHEMBL2808499

SCHEMBL2808499

O=C(NC1(C(=O)NCc2ccc(Nc3ccc(F)cc3C(F)(F)F)cc2)CC1)c1ccno1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
CNR2 P34972 1/20 0.39
BDKRB1 P46663 4/20 0.38
ACE2 Q9BYF1 1/20 0.37
AURKA O14965 3/20 0.36
P2RX7 Q99572 2/20 0.36
CHEK2 O96017 1/20 0.36
CSF1R P07333 1/20 0.36
RET P07949 1/20 0.36
FLT4 P35916 1/20 0.36
ABL2 P42684 1/20 0.36
BLK P51451 1/20 0.36
LIMK1 P53667 1/20 0.36
AURKB Q96GD4 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
OPRL1 P41146 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL185439 0.88 BDKRB1 (0.40) ALDH1A1BDKRB1ACE2AURKACYP3A4
SCHEMBL184742 0.85 CYP3A4 (0.40) ALDH1A1LMNACNR2BDKRB1P2RX7
SCHEMBL13128425 0.84 BDKRB1 (0.48) ALDH1A1LMNACNR2BDKRB1AURKA
SCHEMBL2805899 0.82 BDKRB1 (0.40) CNR2BDKRB1AURKAP2RX7CYP2C19
SCHEMBL186467 0.82 AR (0.41) ALDH1A1LMNACNR2BDKRB1AURKA
SCHEMBL185221 0.82 ALDH1A1 (0.38) ALDH1A1LMNACNR2BDKRB1AURKA
SCHEMBL14865447 0.80 ALDH1A1 (0.36) ALDH1A1LMNACNR2BDKRB1AURKA
SCHEMBL2807564 0.80 LMNA (0.37) ALDH1A1LMNACNR2BDKRB1CYP3A4
SCHEMBL13128556 0.79 CNR2 (0.35) ALDH1A1LMNACNR2BDKRB1AURKA
SCHEMBL2813417 0.78 BDKRB1 (0.41) ALDH1A1LMNACNR2BDKRB1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 ALDH1A1 1000/4885LMNA 2613/4885CNR2 882/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 ALDH1A1 1000/4885LMNA 2613/4885CNR2 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.